MARKET

LCTX

LCTX

Lineage Cell The
AMEX
1.418
-0.002
-0.13%
Opening 09:54 11/28 EST
OPEN
1.420
PREV CLOSE
1.420
HIGH
1.430
LOW
1.410
VOLUME
40.48K
TURNOVER
37.31K
52 WEEK HIGH
2.710
52 WEEK LOW
1.020
MARKET CAP
241.04M
P/E (TTM)
-4.9018
1D
5D
1M
3M
1Y
5Y
What Makes Lineage Cell (LCTX) a New Buy Stock
Lineage Cell (LCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 11/17 17:00
2 “Strong Buy” Penny Stocks That Could See 200% Gains (Or More)
Investors know that the key to profits is in the return – and that means, a willingness to shoulder risk. Risk is relative, of course, and tends to run hand-in-hand with the return potential. Find a stock with a giant return potential, and chances are, you...
TipRanks · 11/17 14:45
Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of -33.33% and 26.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/10 23:35
BRIEF-Lineage Cell Therapeutics Inc Reports Q3 Loss Per Share Of $0.04
Reuters · 11/10 21:14
Lineage Cell Therapeutics Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $3.00M Miss $3.90M Estimate
Benzinga · 11/10 21:07
Lineage Cell Therapeutics GAAP EPS of -$0.04, revenue of $3M
Seekingalpha · 11/10 21:06
-- Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q3 Revenue $3M
-- Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q3 Revenue $3M
MT Newswires · 11/10 16:21
Notable earnings after Thursday's close
Seekingalpha · 11/09 22:35
More
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cell therapies to address unmet medical needs. The Company designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. It has three allogeneic product candidates: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA). OPC1 is an oligodendrocyte progenitor cell therapy, which is in a follow-up for a Phase I/IIa multicenter clinical trial for spinal cord injuries (SCI). VAC is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells. Its VAC product candidates include, VAC2, which is in a Phase I clinical trial in non-small cell lung cancer (NSCLC).

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.